期刊文献+

伏立诺他对卵巢癌SKOV3细胞增殖和凋亡的影响及机制研究

Effect and mechanism of Vorinostat on the proliferation and apoptosis of ovarian cancer SKOV3 cells
暂未订购
导出
摘要 目的探讨伏立诺他对卵巢癌SKOV3细胞增殖和凋亡的影响及机制研究。方法以人卵巢癌SKOV3细胞为研究对象,随机分为空白组、伏立诺他高剂量组、中剂量组和低剂量组共4组,采用CCK-8法测定SKOV3细胞增殖情况,Western blot检测SKOV3细胞H3K4ac和H3K27ac蛋白表达情况,Real-time PCR检测SKOV3细胞Bax mRNA、Bcl-2 mRNA、p53 mRNA、Cyclin D1 mRNA表达。结果 CCK-8法测定结果显示,与空白组比较,伏立诺他低、中、高剂量组增殖明显降低,差异具有统计学意义(P<0.05)。RT-PCR结果显示,与空白组比较,伏立诺他低、中、高剂量组SKOV3细胞中Bcl-2 mRNA和Cyclin D1mRNA表达明显降低,Bax mRNA和p53 mRNA表达明显升高。Western blot结果显示与空白组比较,伏立诺他低、中、高剂量组SKOV3细胞中H3K4ac和H3K27ac蛋白表达明显增加。结论伏立诺他抑制SKOV3细胞增殖,促进凋亡,其机制可能与抑制组蛋白去乙酰化酶活性,激活p53凋亡通路有关。 Objective The aim of this study was to investigate the effects and mechanisms of Volerovel on the proliferation and apoptosis of ovarian cancer SKOV3 cells. Methods Human ovarian cancer SKOV3 cells were treated with the negative control,low,middle and high doses of Vorinostat. The proliferation of SKOV3 cells was determined by CCK-8 assay. Western blot was used to detect the expression of H3 K4 ac and H3 K27 ac protein in SKOV3 cells. Real-time PCR was used to detect the expression of Bax,Bcl-2,p53 and Cyclin D1 in SKOV3 cells. Results Vorinostat at low,middle and high dose groups was significantly decreased proliferation of SKOV3 cells when compared to the blank group. They showed a statistical difference. As compared with the blank group,Vorinostat in the low,medium and high dose groups significantly decreased the expression of Bcl-2 mRNA and Cyclin D1 mRNA,and significantly increased the expression of Bax mRNA and p53 mRNA in SKOV3 cells. Vorinostat significantly increased the expression of H3 K4 ac and H3 K27 ac protein in SKOV3 cells when compared to the negative control group. Conclusion Vorinostat can inhibit the proliferation of SKOV3 cells and promote apoptosis. The mechanism may be related to inhibition of histone deacetylase activity and activation of p53 apoptosis pathway.
作者 梁冠盈 迟秋君 李晓梅 LIANG Guanying;CHI Qiujun;LI Xiaomei(Department of Pathology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Harbin Medical University)
出处 《实用肿瘤学杂志》 CAS 2018年第4期298-302,共5页 Practical Oncology Journal
关键词 卵巢癌SKOV3 组蛋白去乙酰化酶抑制剂 伏立诺他 P53通路 Ovarian cancer SKOV3 cell Histone deacetylase inhibitor Vorinostat p53 pathway
  • 相关文献

参考文献9

二级参考文献85

  • 1商冠宁,王玉名,邱恩铎,孙平.大剂量IFO治疗骨及软组织肉瘤的泌尿系统毒性分析[J].实用癌症杂志,2010,25(5):514-516. 被引量:4
  • 2Monk BJ,Han E,Josephs-Cowan CA,et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxie regimens in advanced refractory epithelial ovarian cancer [J]. Gynecol Onco1,2006,102(2) : 140-144.
  • 3Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent,platinum-refractory,epithelial ovarian carcinoma : A retrospective analysis [J ]. Cancer, 2006,107 ( 1 ) : 83-89.
  • 4Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression- free survival with weekly paelitaxel and bevacizumab in recurrent ovarian cancer [ J ]. Gynecol Oncol,2009,115 (3) : 396-400.
  • 5Garcia AA,Hirte H,Fleming G,et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California,Chicago,and Princess Margaret Hospital phase II consortia [J ]. J Clin Oncol, 2008,26( 1 ) :76-82.
  • 6Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [J]. J Clin Oncol, 2007,25 (33) :5180-5186.
  • 7Burger RA,Sil! MW,Monk BJ,et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer:a Gynecologic Oncology Group study [J ]. J Clin Oncol ,2007,25 (33) :5165-5171.
  • 8Tao X,Sood AK,Deavers MT,et al.Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors [J]. Gynecol Oncol, 2009,114 (3) : 43 1-436.
  • 9Gordon AN,Finkler N,Edwards RP,et al. Efficacy and safety of erlotinib HCI ,an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor,in patients with advanced ovarian carcinoma: results from a phase II muhicenter study[J]. Int J Gynecol Cancer, 2005,15(5) :785-792.
  • 10Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression :a Gynecologic Oncology Group Study [ J ]. Clin Cancer Res, 2005,11 ( 15 ) : 5539-5548.

共引文献150

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部